NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 197 filers reported holding NEVRO CORP in Q4 2019. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2020 | $208,000 | -7.1% | 1,200 | -53.8% | 0.00% | -100.0% |
Q3 2019 | $224,000 | +80.6% | 2,600 | +56.2% | 0.00% | 0.0% |
Q2 2017 | $124,000 | -48.3% | 1,665 | -35.0% | 0.00% | 0.0% |
Q1 2017 | $240,000 | +14.8% | 2,560 | -10.9% | 0.00% | 0.0% |
Q4 2016 | $209,000 | -19.6% | 2,873 | +15.2% | 0.00% | -50.0% |
Q3 2016 | $260,000 | +1757.1% | 2,495 | +1179.5% | 0.00% | – |
Q2 2016 | $14,000 | +100.0% | 195 | +61.2% | 0.00% | – |
Q1 2016 | $7,000 | – | 121 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |